Skip to main content

Want a detailed portfolio tracker?

Performance analysis of MedTech Acquisition (MTAC)

Annual Return

Over the past 3 years, MTAC has had an average annual return of +8.52%, outperforming the benchmark SPY, which returned +4.79% annual.

Over the past 5 years, MTAC has had an average annual return of +6.89%, outperforming the benchmark SPY, which returned +4.15% annual.

Since Feb 8, 2021, MTAC has had an average annual return of +3.04%, underperforming the benchmark SPY, which returned +7.02% annual.

202320222021
+13.06%+1.51%-6.08%

Monthly Return

YearJanFebMarAprMayJunJulAugSepOctNovDecAnnually Total
2023+0.60%+0.30%+0.79%-0.10%+2.16%+0.68%-6.97%+16.30%+13.06%
2022-0.20%+1.01%-1.61%+0.30%-0.10%+0.25%+0.36%+0.40%+0.10%+0.71%+0.60%-0.30%+1.51%
2021-2.28%-6.03%+1.24%-0.82%+0%+0.10%+1.24%+1.02%+0.20%+0.20%-0.90%-6.08%

Drawdown analysis of MedTech Acquisition (MTAC)

The maximum drawdown for the MTAC was -13.92%, occurring on Mar 7, 2022. Recovery took 359 trading sessions.

Since Feb 8, 2021 MTAC has experienced the following drawdowns:

  • 10% or more: 1 time
DepthStartTo BottomBottomTo RecoverEndTotal
-13.92%Feb 19, 2021263Mar 7, 2022359Aug 10, 2023622
-1.90%Feb 8, 20214Feb 12, 20211Feb 16, 20215